Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 9, 2015, Pages

  Cheyne, Leanne ^a   Irvin Sellers, Melanie J ^b   White, John ^c  

^a BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ST PETER S HOSPITAL   (United Kingdom)

^c York Teaching Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; TIOTROPIUM BROMIDE;

ALL CAUSE MORTALITY; BASELINE DYSPNEA INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE ASSESSMENT; REVIEW; SIDE EFFECT; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TRANSITION DYSPNEA INDEX;

EID: 84964693304     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009552.pub3     Document Type: Review

References (39)

1. Oostenbrink JB, Rutten-van Molken MP, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. European Respiratory Journal 2004;23(2):241-9.
2. Van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJG. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000;55(4):289-94.
3. Vincken W, van Noord JA, Greefhorst A, Bantje TA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. European Respiratory Journal 2002;19(2):209-16.
4. 205.251. SPIRIVA ® - Pulmonary Disease, Chronic Obstructive (Clinical trial 205.251). http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview/205/205_251.html (accessed 2 September 2015).
5. 205.252. SPIRIVA ® - Pulmonary Disease, Chronic Obstructive. http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview/205/205_252.html (accessed 2 September 2015).
6. Voshaar T, Lapidus R, Maleki-Yazdi R, Timmer W, Rubin E, Lowe L, et al. A randomized study of tiotropium Respimats Soft MistTM Inhaler vs. ipratropium pMDI in COPD. Respiratory Medicine 2008;102:32-41.
7. Kerwin EM, Fogarty C, Dunn K, Singh D, Tutuncu A. Cardiovascular safety of nebulized glycopyrrolate (SUN-101) compared with tiotropium, ipratropium and placebo in patients with COPD. American Journal of Respiratory and Critical Care Medicine 2013;187:A1483.
8. Kim SJ, Kim MS, Lee SH, Kim YK, Moon HS, Park SH, et al. A comparison of tiotropium 18mug, once daily and ipratropium 40mug, 4 times daily in a double-blind, double-dummy, efficacy and safety study in adults with chronic obstructive pulmonary disease. Tuberculosis and Respiratory Diseases 2005;58(5):498-506.
9. NCT02172443. Comparison of 18 mcg of tiotropium inhalation capsules and atrovent metered dose inhaler (2 puffs of 20 mcg) in a double blind, double dummy, efficacy and safety study in adults with chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT02172443 (accessed 1 September 2015).
10. NCT02172469. A comparison of 18 μg of tiotropium inhalation capsules and Atrovent® metered dose inhaler (2 puffs of 20 μg, 4 times daily) in a double-blind, double-dummy, efficacy and safety study in adults with chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/study/NCT02172469 (accessed 1 September 2015).
11. Niewoehner DE, Lapidus R, Cote C, Sharafkhaneh A, Plautz M, Johnson P, et al. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics 2009;22(6):587-92.
12. Serby CW, Schwartzstein RM, Jones PW, Ries AL, Killian KJ. Tiotropium: 1-Yr studies versus placebo/ipratropium. European Respiratory Review 2002;12(82):40-2.
13. Wang HY, Xiao Y, Shi LL, Gong Q, Wen ZG. Study on efficacy and safety of tiotropium powder in patients with stable COPD. Chinese Journal of New Drugs 2007;16(14):1119-22.
14. Zheng JP, Kang J, Cai BQ, Zhou X, Cao ZL, Bai CX, et al. Comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a randomized, double-blind, double-dummy, efficacy and safety study in patients with chronic obstructive pulmonary disease. Chinese Journal of Tuberculosis and Respiratory Diseases 2006;29(6):363-7.
15. Barnes P. The pharmacological properties of tiotropium. Chest 2000;117:63S.
16. Barr RG, Bourbeau J, Camargo Carlos A. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI:]
17. British National Formulary. www.bnf.org (accessed 1 November 2011).
18. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137(1):20-30.
19. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013;68(1):48-56.
20. GOLD. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf (accessed 2 September 2015).
21. Great Britain. Commission for Healthcare Audit and Inspection. Clearing the air: A national study of chronic obstructive pulmonary disease. Healthcare Commission. The Healthcare Commission (Jun. 2006), 2006.
22. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
23. Karner C, Cates CJ. The added effect of inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI:]
24. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI:]
25. Karner C, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI:]
26. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI:]
27. ® in the treatment of COPD: A safety review. International Journal of Chronic Obstructive Pulmonary Disease 2009;4:397-409.
28. Lubinski W. Tiotropium as a controller of bronchoconstriction. Polski Merkuriusz Lekarski 2004;16:75-76, 78.
29. NICE. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). https://www.nice.org.uk/guidance/cg101 (accessed 2 September 2015).
30. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010;137(1):13-9. [: 0012-3692]
31. Ram FS. Tiotropium mist inhaler for COPD increases risk of mortality compared with placebo. Evidence Based Medicine 2011;16(6):189-90.
32. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
33. Salpeter R, Buckley N, Salpeter E. Meta-analysis: Anticholinergics, but not beta agonists, reduce severe exacerbations and respiratory mortality in COPD. Journal of General Internal Medicine 2006;21(10):1011-9.
34. Sears M, Hamilton M. Long-acting bronchodilators in COPD. Chest 2008;133(5):1057-8.
35. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(12):1439-50.
36. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 2013;68(1):114-6.
37. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI:]
38. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium respimat inhaler and the risk of death in COPD. New England Journal of Medicine 2013;369(16):1491-501.
39. Yohannes AW, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: A meta-analysis of clinically relevant outcomes. Respiratory Care 2011;56(4):477-87.